Orca-T Approved to Prevent GVHD After Stem Cell Transplant for Blood Cancers

The FDA approved Orca-T (Tregzi), an allogeneic regulatory T cell-based immunotherapy product combined with hematopoietic stem and progenitor cells and T cells, to prevent graft-versus-host disease (GVHD) in stem cell transplants for hematologic cancers.